Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10163 Neoplasms 7801 Carcinoma, Non-Small-Cell Lung 5744 Prostatic Neoplasms 5016 Colorectal Neoplasms 4588 Lung Neoplasms 3716 Leukemia, Myeloid, Acute 3097 Neoplasm Metastasis 3074 Multiple Myeloma 3073 Pancreatic Neoplasms 2837 Melanoma 2646 Lymphoma 2569 Ovarian Neoplasms 2565 Carcinoma, Hepatocellular 2473 Stomach Neoplasms 2325 Recurrence 2221 Head and Neck Neoplasms 2095 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2084 Lymphoma, Non-Hodgkin 2055 Leukemia 2011 Brain Neoplasms 1899 Glioblastoma 1791 Colonic Neoplasms 1790 Leukemia, Lymphocytic, Chronic, B-Cell 1771 Rectal Neoplasms 1714 Uterine Cervical Neoplasms 1684 Lymphoma, Follicular 1651 Squamous Cell Carcinoma of Head and Neck 1649 Lymphoma, Large B-Cell, Diffuse 1596 Carcinoma, Renal Cell 1574

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumor × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡